We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current LABFF market cap is 4.51B. The company's latest EPS is EUR 3.2524 and P/E is 5.09.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 381.31M | 419.96M | 648.68M | 817.7M | 829.51M |
| Operating Income | 41.84M | 73.49M | 181.57M | 256.05M | 220.13M |
| Net Income | 39.27M | 61.06M | 153.08M | 199.67M | 170.34M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 511.21M | 574.44M | 732.68M | 878.7M | 799.88M |
| Total Liabilities | 188.83M | 200.74M | 261.7M | 357.32M | 256.39M |
| Total Equity | 322.39M | 373.7M | 470.98M | 521.38M | 543.49M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -9.19M | 48.88M | 149.44M | 237.6M | 113.25M |
| Investing | -40.47M | -39.63M | -40.84M | -57.15M | -52.03M |
| Financing | 21.43M | -21.52M | -62.73M | -154.54M | -160.84M |
| Market Cap | 4.51B |
| Price to Earnings Ratio | 5.09 |
| Price to Sales Ratio | 1.04 |
| Price to Cash Ratio | 34.23 |
| Price to Book Ratio | 1.59 |
| Dividend Yield | - |
| Shares Outstanding | 52.37M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 69.12% |
| 52 Week High | 86.05 |
| 52 Week Low | 50.88 |
| Spread (Intraday) | 5 (5.19%) |
| Company Name | Laboratorios Farmaceuticos Rovi SA (PK) |
| Address |
calle julian camarillo, 35 madrid, community of madrid 28223 |
| Website | https://www.rovi.es |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
